Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from the authors.

Stranzenbach, R; Dippel, E; Schlaak, M; Stadler, R

Stranzenbach, R; Dippel, E; Schlaak, M; Stadler, R.

Afiliação

Stranzenbach R; Department of Dermatology, Venerology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Bochum, Germany.
Dippel E; Department of Dermatology, Klinikum Ludwigshafen, Skin Cancer Centre Rheinpfalz, Ludwigshafen, Germany.
Schlaak M; Department of Dermatology and Venereology, University Hospital Cologne, Skin Cancer Center at Center of Integrated Oncology (CIO Koeln Bonn), Cologne, Germany.
Stadler R; Department of Dermatology, Venerology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Bochum, Germany.

Br J Dermatol ; 178(1): 303, 2018 01.

Article em En | MEDLINE | ID: mdl-28889619

Assuntos

Imunoconjugados; Antígeno Ki-1; Brentuximab Vedotin; Humanos; Linfoma Cutâneo de Células T

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno Ki-1 / Imunoconjugados Limite: Humans Idioma: En Revista: Br J Dermatol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google